Among O
the O
cases O
treated O
with O
pyrantel O
, O
the O
egg B-Physiological-Clinical
negative O
conversion B-Life-Impact

Oral B-Physiological-Clinical
mucositis B-Physiological-Clinical
was O
analyzed O
using O
the O
unadjusted O
chi-square O
test O
, O
and O
time O
to O
first B-Physiological-Clinical
episode I-Physiological-Clinical

Cervical B-Physiological-Clinical
artery I-Physiological-Clinical
spasm I-Physiological-Clinical

RESULTS O
Relative O
to O
the O
group O
B O
, O
the O
group O
A O
had O
( O
1 O
) O
a O
significant O
decrease O
of O
pain B-Physiological-Clinical
at I-Physiological-Clinical
rest I-Physiological-Clinical
at O
the O
end O
of O
8 O
weeks O
of O
the O
treatment O
( O
p O
< O
0.005 O
) O
and O
at O
the O
end O
of O
following O
up O
period O
( O
p O
< O
0.05 O
) O
, O
( O
2 O
) O
a O
significant O
decrease O
in O
pain B-Physiological-Clinical
at I-Physiological-Clinical
palpation I-Physiological-Clinical
and O
pain B-Physiological-Clinical
on I-Physiological-Clinical
isometric I-Physiological-Clinical
testing I-Physiological-Clinical
at O
8 O
weeks O
of O
treatment O
( O
p O
< O
0.05 O
) O
, O
and O
at O
8 O
weeks O
follow-up O
( O
p O
< O
0.001 O
) O
, O
( O
3 O
) O
a O
significant O
decrease O
in O
pain B-Physiological-Clinical
during I-Physiological-Clinical
middle I-Physiological-Clinical
finger I-Physiological-Clinical
test I-Physiological-Clinical
at O
the O
end O
of O
8 O
weeks O
of O
treatment O
( O
p O
< O
0.01 O
) O
, O
and O
at O
the O
end O
of O
the O
follow-up O
period O
( O
p O
< O
0.05 O
) O
, O
( O
4 O
) O
a O
significant O
decrease O
of O
pain B-Physiological-Clinical
during I-Physiological-Clinical
grip I-Physiological-Clinical
strength I-Physiological-Clinical
testing I-Physiological-Clinical
at O
8 O
weeks O
of O
treatment O
( O
p O
< O
0.05 O
) O
, O
and O
at O
8 O
weeks O
follow-up O
( O
p O
< O
0.001 O
) O
, O
( O
5 O
) O
a O
significant O
increase O
in O
the O
wrist B-Physiological-Clinical
range O
of O
motion B-Life-Impact
at O
8 O
weeks O
follow-up O
( O
p O
< O
0.01 O
) O
, O
( O
6 O
) O
an O
increase O
in O
grip B-Life-Impact

However O
, O
the O
cortisol B-Physiological-Clinical
response O
to O
weaning B-Physiological-Clinical
was O
increased O
in O
LP O
piglets O
( O
P O
< O
0.05 O
) O
, O
and O
in O
HP O
offspring O
the O
basal B-Physiological-Clinical
plasma B-Physiological-Clinical
noradrenaline I-Physiological-Clinical

In O
peripheral O
blood O
monocytes O
, O
human B-Physiological-Clinical
leukocyte I-Physiological-Clinical
antigen-DR I-Physiological-Clinical
expression I-Physiological-Clinical
was O
only O
slightly O
depressed O
, O
whereas O
in O
vitro B-Physiological-Clinical
phagocytosis I-Physiological-Clinical
and O
the O
monocyte-activating B-Physiological-Clinical
cytokine I-Physiological-Clinical

The O
incidence O
of O
serious B-Adverse-effects
adverse I-Adverse-effects

Tryptophan O
depletion O
led O
to O
a O
significant O
increase O
in O
behaviors O
such O
as O
whirling B-Physiological-Clinical
, O
flapping B-Life-Impact
, O
pacing B-Life-Impact
, O
banging B-Life-Impact
and O
hitting B-Life-Impact

Similarly O
, O
nonsignificant O
changes O
were O
detected O
for O
the O
fibrinolytic B-Physiological-Clinical
parameters I-Physiological-Clinical
tissue I-Physiological-Clinical
plasminogen I-Physiological-Clinical
activator B-Physiological-Clinical
activity I-Physiological-Clinical
, O
tissue B-Physiological-Clinical
plasminogen I-Physiological-Clinical

CONCLUSIONS O
These O
results O
provide O
further O
evidence O
that O
use O
of O
ecstasy O
may O
be O
associated O
with O
impairment O
of O
memory B-Life-Impact
and O
of O
serotonergic B-Physiological-Clinical

In O
Experiment O
2 O
, O
thirty-two O
4 O
- O
to O
5-year-olds O
learned O
from O
scenarios O
lacking O
pretend O
speech B-Life-Impact
or I-Life-Impact
sound I-Life-Impact

Enalapril O
therapy O
did O
not O
affect O
left O
ventricle B-Physiological-Clinical
diastolic I-Physiological-Clinical

The O
most O
common O
nasal B-Physiological-Clinical
and O
non-nasal B-Physiological-Clinical
adverse B-Adverse-effects

At O
week O
84 O
, O
HBV B-Physiological-Clinical

There O
were O
no O
significant O
differences O
between O
the O
results O
of O
the O
two O
visits O
neither O
with O
the O
VAS O
nor O
with O
the O
SGRQ O
on O
the O
QoL B-Life-Impact

The O
oats O
group O
experienced O
a O
significant O
reduction O
in O
both O
total O
cholesterol B-Physiological-Clinical
( O
9 O
% O
) O
and O
low-density B-Physiological-Clinical

Several O
additional O
items O
measuring O
tantrum-like B-Life-Impact

RESULTS O
Acupuncture O
compared O
with O
oral O
care O
, O
produced O
significant O
reductions O
in O
patient O
reports O
of O
severe B-Physiological-Clinical
dry I-Physiological-Clinical
mouth B-Physiological-Clinical
( O
OR O
= O
2.01 O
, O
P O
= O
0.031 O
) O
sticky B-Physiological-Clinical
saliva I-Physiological-Clinical
( O
OR O
= O
1.67 O
, O
P O
= O
0.048 O
) O
, O
needing B-Physiological-Clinical
to O
sip B-Physiological-Clinical
fluids I-Physiological-Clinical

RESULTS O
Total O
AOFAS B-Physiological-Clinical
Ankle-Hindfoot I-Physiological-Clinical
score O
of O
OA B-Physiological-Clinical

MAIN O
OUTCOME O
MEASURE O
The O
main O
outcome O
measure O
was O
the O
antiplatelet B-Physiological-Clinical
activity I-Physiological-Clinical
of I-Physiological-Clinical
ASA I-Physiological-Clinical
, O
as O
assessed O
by O
ARU B-Resource-use
ratio O
relative O
to O
baseline O
in O
the O
VerifyNow O
ASA O
assay O
; O
suppression O
of O
serum B-Physiological-Clinical
thromboxane I-Physiological-Clinical
B I-Physiological-Clinical
( I-Physiological-Clinical
2 I-Physiological-Clinical
) I-Physiological-Clinical
( I-Physiological-Clinical

A O
decrease O
was O
found O
in O
the O
number O
of O
blood B-Physiological-Clinical
monocytes I-Physiological-Clinical
and O
the O
number O
of I-Physiological-Clinical
monocytes B-Physiological-Clinical
capable I-Physiological-Clinical
of I-Physiological-Clinical
transforming I-Physiological-Clinical

